Meeting
2013 ASCO Annual Meeting
A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
Authors
Geoffrey Shapiro
Dana-Farber Cancer Institute, Boston, MA
Geoffrey Shapiro , Jeffrey G Supko , Daniel C. Cho , John Frederick Hilton , Matthew Hadfield , Solida Pruitt-Thompson , Eveline Bordoli-Trachsela , Nela Zvereva , Andrew Wolanski , Aya Sato-DiLorenzo , Susan Gotthardt , Edward A. Fox , Sigitas Jonas Verselis , Ashok Kumar , Sylvia A. Holden , Siya Ram , Karima Chafai-Fadela , Kimberly Harding , Krishna E. Menon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Signal Transduction
Clinical Trial Registration Number
NCT01664000
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS2627)
DOI
10.1200/jco.2013.31.15_suppl.tps2627
Abstract #
TPS2627
Poster Bd #
12G
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
First Author: Geoffrey Shapiro
Poster
2020 ASCO Virtual Scientific Program
Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.
First Author: Xing Zhang
Poster
2019 ASCO Annual Meeting
A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
First Author: Drew W. Rasco
Poster
2018 ASCO Annual Meeting
A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma(WD/DD LPS), solid tumors (ST) and lymphomas (L).
First Author: Todd Michael Bauer